ArticlemAbs2015
Antibody-drug conjugates: Intellectual property considerations.
Article in mAbs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- An update on patent issues regarding antibody-drug conjugates.Nature biotechnology · 2026Article
- Recent Technological and Intellectual Property Trends in Antibody-Drug Conjugate Research.Pharmaceutics · 2024Review
- Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates.Chemical science · 2021Review
- Enriching cancer pharmacology with drugs of marine origin.British journal of pharmacology · 2020Review
- Marine drugs for cancer: surfacing biotechnological innovations from the oceans.Clinics (Sao Paulo, Brazil) · 2018Review
- Patent trend and competitive analysis of cancer immunotherapy in the United States.Human vaccines & immunotherapeutics · 2017Article
- Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Marine drugs · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates are highly complex entities that combine an antibody, a linker and a toxin. This complexity makes them demanding both technically and from a regulatory point of view, and difficult to deal with in their patent aspects. This article discusses different issues of patent protection and freedom to operate with regard to this promising new class of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.